Clinical Trials in Review
Panelists discuss the evolving clinical trial landscape in non–clear cell renal cell carcinoma, highlighting ongoing studies of combination therapies integrating TKIs and immuno-oncology agents, the challenges of rare subtypes, and the critical role of trials and support networks in advancing personalized treatment options.
The landscape of clinical trials for non–clear cell renal cell carcinoma (RCC) is evolving rapidly, moving beyond traditional single-agent therapies. Current studies are increasingly focused on combining targeted therapies, such as tyrosine kinase inhibitors (TKIs), with immuno-oncology agents. One key phase 3 trial is investigating a novel combination therapy against the long-standing standard of care, Sunitinib, specifically in the non–clear cell RCC population. This study employs a 2:1 randomization and primarily measures progression-free survival and objective response rates, aiming to clarify whether combination treatments provide superior outcomes compared to monotherapy. This shift reflects the broader trend in oncology toward integrating immune checkpoint inhibitors with targeted agents to enhance efficacy.
Another important ongoing trial is a randomized phase 2 study concentrating on metastatic papillary RCC. This study compares a combination of cabozantinib and atezolizumab, a PD-L1 inhibitor, to cabozantinib alone. The primary focus is on progression-free survival, with additional end points including overall survival, response rates, and safety. This trial addresses an essential clinical question: How much benefit does immunotherapy add in these less common RCC subtypes? Although the immunotherapy agent used may not be the most favored choice currently, the trial’s design allows for important insights into the role of immune modulation in papillary RCC.
Looking ahead, there is optimism about several new trials exploring a variety of novel drug combinations and molecularly targeted approaches across different non–clear cell RCC histologies. Challenges remain, including limited trial availability across institutions and the complexity of these rare diseases, which often require highly tailored approaches. Still, clinical trials represent the best opportunity for patients to access cutting-edge therapies and contribute to advancing knowledge in this underserved population. Additionally, patient resources and support networks play a crucial role in helping navigate treatment options and clinical trial enrollment, underscoring the importance of comprehensive care beyond the clinic.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
